Granted Patent
B2
US 12,208,144 · App. 17/206,878 · Granted Jan 28, 2025
Intrathecal delivery of recombinant adeno-associated virus 9
Inventors:
Brian K. Kaspar (Columbus, OH); Arthur Burghes (Columbus, OH); Paul Porensky (Columbus, OH)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as SMA and ALS as well as Pompe disease and lysosomal storage disorders. It is disclosed that administration of a non-ionic, low-os-molar contrast agent, together with a rAA9 vector for the expression of Survival Motor Neuron protein, improves the survival of SMN mutant mice as compared to the administration of the expression vector alone.
Claims (10)
1. A method of treating a lysosomal storage disorder associated with a mutation in the TPP1 gene in a patient in need thereof, the method comprising: intrathecally administering a) a recombinant AAV9 (rAAV9) comprising an rAAV9 genome comprising a neuronal ceroid lipofuscinosis 2 (CLN2) gene wherein the gene is operatively linked to an expression control sequence; and (b) a non-ionic, low-osmolar contrast agent, wherein the intrathecal administration of the composition results in delivery of the CLN2 gene to the central nervous system (CNS) of the patient.
2. The method of claim 1 , wherein the non-ionic, low-osmolar contrast agent is selected from the group consisting of iobitridol, iohexol, iomeprol, iopamidol, iopentol, iopromide, ioversol, ioxilan, and combinations thereof.
3. The method of claim 1 , wherein the non-ionic, low-osmolar contrast agent is iohexol.
4. The method of claim 1 , wherein the rAAV9 genome is a single-stranded genome.
5. The method of claim 1 , wherein the rAAV9 genome is a self-complementary genome.
6. A method of delivering CLN2 gene to CNS of a patient in need thereof, comprising intrathecally administering to the patient a composition comprising a) a rAAV9 comprising an rAAV9 genome comprising a CLN2 gene wherein the gene is operatively linked to an expression control sequence and (b) a non-ionic, low-osmolar contrast agent—wherein the intrathecal administration of the composition results in delivery of the CLN2 gene to the CNS of the patient.
7. The method of claim 6 , wherein the non-ionic, low-osmolar contrast agent is selected from the group consisting of iobitridol, iohexol, iomeprol, iopamidol, iopentol, iopromide, ioversol, ioxilan, and combinations thereof.
8. The method of claim 6 , wherein the non-ionic, low-osmolar contrast agent is iohexol.
9. The method of claim 6 , wherein the rAAV9 genome is a single-stranded genome.
10. The method of claim 6 , wherein the rAAV9 genome is a self-complementary genome.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 18, 2024
From: PORENSKY, PAUL N.; BURGHES, ARTHUR H. M.
To: OHIO STATE INNOVATION FOUNDATION
Reel/Frame 068940/0211 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 1, 2024
From: KASPAR, BRIAN K.
To: NATIONWIDE CHILDREN'S HOSPITAL
Reel/Frame 068757/0733 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 1, 2024
From: PORENSKY, PAUL N.
To: OHIO STATE INNOVATION FOUNDATION
Reel/Frame 068758/0013 →
Continuity (4)
Continuation
14417823
Provisional Application
61678458
· Aug 1, 2012
References Cited (248)
US 5173414A
· Lebkowski et al.
· 1992
[cited by applicant]
US 5658776A
· Flotte et al.
· 1997
[cited by applicant]
US 5786211A
· Johnson
· 1998
[cited by applicant]
US 5871982A
· Wilson et al.
· 1999
[cited by applicant]
US 6258595B1
· Gao et al.
· 2001
[cited by applicant]
US 6566118B1
· Atkinson et al.
· 2003
[cited by applicant]
US 6582692B1
· Podsakoff et al.
· 2003
[cited by applicant]
US 6841357B1
· Vaillancourt et al.
· 2005
[cited by applicant]
US 7198951B2
· Gao et al.
· 2007
[cited by applicant]
US 7906111B2
· Wilson et al.
· 2011
[cited by applicant]
US 9415121B2
· Kaspar et al.
· 2016
[cited by applicant]
US 9725716B2
· Burghes et al.
· 2017
[cited by applicant]
US 9926574B2
· Barkats
· 2018
[cited by applicant]
US 20020192688A1
· Yang et al.
· 2002
[cited by applicant]
US 20030083299A1
· Ferguson
· 2003
[cited by applicant]
US 20040076613A1
· Mazarakis et al.
· 2004
[cited by applicant]
US 20070280906A1
· Petras
· 2007
[cited by applicant]
US 20120177605A1
· Kaspar et al.
· 2012
[cited by applicant]
US 20120253261A1
· Poletto et al.
· 2012
[cited by applicant]
US 20120322861A1
· Byrne
· 2012
[cited by examiner]
US 20130039888A1
· McCarty et al.
· 2013
[cited by applicant]
US 20130195800A1
· Roeth et al.
· 2013
[cited by applicant]
US 20130287736A1
· Passini et al.
· 2013
[cited by applicant]
US 20150252384A1
· Kaspar et al.
· 2015
[cited by applicant]
US 20170216458A1
· Kaspar et al.
· 2017
[cited by applicant]
US 20180036431A1
· Kaspar et al.
· 2018
[cited by applicant]
CN 101137755
· 2004
[cited by examiner]
EP 1620133A1
· 2006
[cited by applicant]
JP 2007527427A
· 2007
[cited by applicant]
JP 2007528424A
· 2007
[cited by applicant]
JP 2015525565A
· 2015
[cited by applicant]
WO WO9513365A1
· 1995
[cited by applicant]
WO WO9513392A1
· 1995
[cited by applicant]
WO WO9617947A1
· 1996
[cited by applicant]
WO WO9706243A1
· 1997
[cited by applicant]
WO WO9708298A1
· 1997
[cited by applicant]
WO WO9708308A1
· 1997
[cited by applicant]
WO WO9709441A2
· 1997
[cited by applicant]
WO WO9721825A1
· 1997
[cited by applicant]
WO WO9809657A2
· 1998
[cited by applicant]
WO WO9911764A2
· 1999
[cited by applicant]
WO WO200183692A2
· 2001
[cited by applicant]
WO WO2002081634A2
· 2002
[cited by applicant]
WO WO2004098648A1
· 2004
[cited by applicant]
WO WO2005084713A2
· 2005
[cited by applicant]
WO WO2005087272A2
· 2005
[cited by applicant]
WO WO2007089632A2
· 2007
[cited by applicant]
WO WO2009013290A1
· 2009
[cited by applicant]
WO WO2009043936A1
· 2009
[cited by applicant]
WO WO2009137006A2
· 2009
[cited by applicant]
WO WO2010071832A1
· 2010
[cited by applicant]
WO WO2010088560
· 2010
[cited by examiner]
WO WO20100129021A1
· 2010
[cited by applicant]
WO WO2011112902A2
· 2011
[cited by applicant]
WO WO2011133890A1
· 2011
[cited by applicant]
Crystal, RG, et al (2004) Clinical protocol Administration of a replication- deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal cer…
[cited by examiner]
Duque et al, Intravenous Administration of Self-complementary AAV9 Enables Transgene Delivery to Adult Motor Neuron, Molecular Therapy, 2009, pp. 1187-1196.
[cited by examiner]
Wang et al, translation of CN 101137755, EFD Apr. 14, 2004.
[cited by examiner]
Jalanko et al, Neuronal ceroid lipofuscinoses , Biochimica et Biophysica Acta, 2009, pp. 697-709.
[cited by examiner]
Abbott et al., Astrocyte-endothelial interactions at the blood-brain barrier, Nat. Rev. Neurosci., 7(1):41-53 (2006).
[cited by applicant]
Abbott et al., Transporting therapeutics across the blood-brain barrier, Mol. Med. Today, 2(3):106-13 (1996).
[cited by applicant]
Abbott, Astrocyte-endothelial interactions and blood-brain barrier permeability, J. Anat., 200(6):629-38 (2002).
[cited by applicant]
Abbott, pp. 189-208, IN: Dermietzel et al. (eds.), Blood-Brain Interfaces—From Ontology to Artificial Barriers, Wiley-VCH Weinheim Germany (2006).
[cited by applicant]
Akbar et al., The role of MR myelography with intrathecal gadolinium in localization of spinal CSF leaks in patients with spontaneous intracranial hypotension, AJNR Am. J. Neuroradiol. 33:535-40(2012).
[cited by applicant]
Al-Sarraf et al., Changes in the kinetics of the acidic amino acid brain and CSF uptake during development in the rat, Brain Res. Dev. Brain Res., 102(1):127-34 (1997).
[cited by applicant]
Amicus Therapeutics, Amicus establishes gene therapy pipeline for Lysosomal storage disorders (LSDs). Sep. 20, 2018, p. 1-27 (2018).
[cited by applicant]
Avila et al., Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy, J. Clin. Invest., 117(3):659-71 (2007).
[cited by applicant]
Ayuso et al., High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency, Gene Ther., 17(4):503-10 (2010).
[cited by applicant]
Azzouz et al., Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy, J. Clin. Invest., 114(12):1726-31 (2004).
[cited by applicant]
Azzouz et al., VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model, Nature, 429(6990):413-7 (2004).
[cited by applicant]
Ballas et al., Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology, Nat. Neurosci., 12(3):311-7 (2009).
[cited by applicant]
Bauer et al., Neural induction of the blood-brain barrier: still an enigma, Cell Mol. Neurobiol., 20(1):13-28 (2000).
[cited by applicant]
Baughan et al., Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector, Mol. Ther., 14(1):54-62 (2006).
[cited by applicant]
Begley et al., Structural and functional aspects of the blood-brain barrier, Prog. Drug Res., 61:40-78 (2003).
[cited by applicant]
Behnsen, Zeit Zellforsch Mikrosk Anat., 4:515-72 (1905).
[cited by applicant]
Bevan et al., Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders, Mol. Ther., 19(11):1971-80 (2011).
[cited by applicant]
Bowerman et al., Therapeutic strategies for spinal muscular atrophy: SMN and beyond,
[cited by applicant]
Bryan et al., Implications of protein fold switching, Curr. Opin. in Struct. Biol., 23(2): 314-316, (2013).
[cited by applicant]
Butchbach et al., Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy, Neurobiol. Dis., 27(2):207-19 (2007).
[cited by applicant]
Cabrera-Salazar et al., Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease,
[cited by applicant]
Caley et al., Development of the blood vessels and extracellular spaces during postnatal maturation of rat cerebral cortex, J. Comp. Neurol., 138(1):31-47 (1970).
[cited by applicant]
Carter, “Adeno-Associated Virus Vectors in Clinical Trials”, Human Gene Therapy, 16:541-550 (2005).
[cited by applicant]
Carter, Adeno-associated virus vectors, Curr. Opin. Biotechnol., 1533-539 (1992).
[cited by applicant]
Cearley et al., Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain, Mol. Ther., 16(10):1710-8 (2008).
[cited by applicant]
Cearley et al., Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain, Mol. Ther., 13(3):528-37 (2006).
[cited by applicant]
Chang et al., Treatment of spinal muscular atrophy by sodium butyrate, Proc. Natl. Acad. Sci. USA, 98(17):9808-13 (2001).
[cited by applicant]
Chen et al., Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice, Nat. Genet., 27(3):327-31 (2001).
[cited by applicant]
Clark et al., A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors, Gene Ther., 3(12):1124-32 (1996).
[cited by applicant]
Clark et al., Development of enzymes of energy metabolism in the neonatal mammalian brain, Dev. Neurosci., 15(3-5):174-80 (1993).
[cited by applicant]
Clark et al., Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses, Hum. Gene Ther., 10(6):1031-9 (1999).
[cited by applicant]
Costa et al., Developmental neuropathology of environmental agents, Annu. Rev. Pharmacol. Toxicol., 44:87-110 (2004).
[cited by applicant]
Cotman et al., Cin3Dex7/8 knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth,
[cited by applicant]
Cressant et al., Improved Behavior and Neuropathology in the Mouse Model of Sanfilippo Type IIIB Disease after Adeno-Associated Virus-Mediated Gene Transfer in the Striatum,
[cited by applicant]
Cserr et al., Blood-brain interfaces in vertebrates: a comparative approach, Am. J. Physiol., 246:277-87 (1984).
[cited by applicant]
Davson et al., Symposium on membrane transport. Transport in the central nervous system, Proc. R. Soc. Med., 60(4):326-9 (1967).
[cited by applicant]
Dayton et al., The advent of AAV9 expands applications for brain and spinal cord gene delivery,
[cited by applicant]
De et al., High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh. 10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses, Mol. T…
[cited by applicant]
De los Reyes et al., Abstract #204. Interim Results from the First Clinical Gene Therapy Trial for CLN6 Batten Disease. Forty-Eighth National Meeting of the Child Neurology Society. Charlotte, NC. Oct. 23-26, 2019.
[cited by applicant]
Dehouck et al., An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro, J. Neurochem., 54(5):1798-801 (1990).
[cited by applicant]
Del Gaudio et al., Increased MECP2 gene copy number as the result of genomic duplication in neurodevelopmentally delayed males, Genet. Med., 8(12):784-92 (2006).
[cited by applicant]
Dodge et al., Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity, Mol. Ther., 16(6):1056-64 (2008).
[cited by applicant]
Dominguez et al., Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice, Hum. Molec. Gen. 20(4):681-693 (2011).
[cited by applicant]
Drory et al., EEG Recordings Following Intrathecal Iohexol Administration,
[cited by applicant]
Eck et al., Gene-based therapy, Chapter 5 pp. 77-101, IN: Goodman & Gilman's The Pharmacological Basis of Therapeutics, New York, NY: McGraw Hill (1996).
[cited by applicant]
Federici et al., Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs, Gene Ther., 19(8):852-9 (2012).
[cited by applicant]
Ford, Selected maturational changes observed in the postnatal rat brain, Prog. Brain Res., 40(0):1-12 (1973).
[cited by applicant]
Foust et al., Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes, Nat. Biotechnol., 27(1):59-65 (2009).
[cited by applicant]
Foust et al., Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN, Nat. Biotechnol., 28(3):271-4 (2010).
[cited by applicant]
Fraldi et al., Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes, Human Molecular Genetics. 16:2693-2702(2007) .
[cited by applicant]
Friez et al., Recurrent infections, hypotonia, and mental retardation caused by duplication of MECP2 and adjacent region in Xq28,
[cited by applicant]
Fu et al., Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain, Mol. Ther., 8(6):911-7 (2003).
[cited by applicant]
Gadalla et al., Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice,
[cited by applicant]
Gao et al., Clades of Adeno-associated viruses are widely disseminated in human tissues, J. Virol., 78(12):6381-8 (2004).
[cited by applicant]
Gao et al., Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse,
[cited by applicant]
Gavrilina et al., Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect, Hum. Mol. Genet., 17(8):1063-75 (2008).
[cited by applicant]
Genetics Home Reference, 2020, Lister Hill Natinal Center for Biomedical Communications, US National Library of Medicine, NIH, DHHS, p. 1-6.
[cited by applicant]
Grady et al., Cerebellar synaptic defects and abnormal motor behavior in mice lacking alpha- and beta-dystrobrevin, J. Neurosci., 26(11):2841-51 (2006).
[cited by applicant]
Gray et al., Viral vectors and delivery strategies for CNS gene therapy,
[cited by applicant]
Griffey et al., CNS-Directed AAV2-Mediated Gene Therapy Ameliorates Functional Deficits in a Murine Model of Infantile Neuronal Ceroid Lipofuscinosis,
[cited by applicant]
Guy et al., A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome,
[cited by applicant]
Guy et al., Reversal of neurological defects in a mouse model of Rett syndrome, Science, 315(5815):1143-7 (2007).
[cited by applicant]
Haria et al., Iohexol a review of its pharmacological properties and use as a contrast medium in Myelography and Neuroangiography.
[cited by applicant]
Haseloff et al., In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro, Cell Mol. Neurobiol., 25(1):25-39 (2005).
[cited by applicant]
Hawkins et al., The blood-brain barrier/neurovascular unit in health and disease, Pharmacol. Rev., 57(2):173-85 (2005).
[cited by applicant]
Hayashi et al., Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes, Glia, 19(1):13-26 (1997).
[cited by applicant]
Hermonat et al., Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells, Proc. Natl. Acad. Sci. USA, 81(20):6466-70 (1984).
[cited by applicant]
Highlights of Prescribing Information Omnipaque- iohexol injection, GE Healthcare Inc. (May 2018).
[cited by applicant]
Hsieh-Li et al., A mouse model for spinal muscular atrophy, Nat. Genet., 24(1):66-70 (2008).
[cited by applicant]
Hudry et al., Therapeutic AAV gene transfer to the newvous system: A clinical reality, Neuron 101, 839-62 (Mar. 6, 2019).
[cited by applicant]
Iadecola, Neurovascular regulation in the normal brain and in Alzheimer's disease, Nat. Rev. Neurosci., 5(5):347-60 (2004).
[cited by applicant]
Inagaki et al., Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8, Mol. Ther., 14(1):45-53 (2006).
[cited by applicant]
Inagaki, et al., “Robust Systemic Transduction with AAV9 Vectors in Mice: Efficient Global Cardiac Gene Transfer Superior to That of AAV8,” Molecular Therapy, vol. 14, No. 1, pp. 45-53 (Jul. 2006).
[cited by applicant]
Kaiser, Clinical research. Death prompts a review of gene therapy vector, Science, 317(5838):580 (2007).
[cited by applicant]
Kaminsky and Ascano, Rett Syndrome Gene Therapy: Understanding the Published Data, (2017).
[cited by applicant]
Kaplitt et al., Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial, Lancet, 369(9579):2097-105 (2007).
[cited by applicant]
Kaspar et al., Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model, Science, 301(5634):839-42 (2003).
[cited by applicant]
Katz et al., Preclinical research in Rett syndrome: setting the foundation for translational success, Dis. Model Mech., 5(6):733-45 (2012).
[cited by applicant]
Kempermann et al., Genetic influence on neurogenesis in the dentate gyrus of adult mice, Proc. Natl. Acad. Sci. USA, 94(19):10409-14 (1997).
[cited by applicant]
Klein et al., AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method, Mol. Ther., 16(1):89-96 (2008).
[cited by applicant]
Kohan et al., Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses, Curr. Pharm. Biotechnol., 12(6):867-83 (2011).
[cited by applicant]
Kong et al., Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice, J. Neurosci., 29(3):842-51 (2009).
[cited by applicant]
Kota et al., Follistatin gene delivery enhances muscle growth and strength in nonhuman primates, Sci. Transl. Med., 1:6-15 (2009).
[cited by applicant]
Kotterman et al., Engineering adeno-associated viruses for clinical gene therapy,
[cited by applicant]
Laughlin et al., Cloning of infectious adeno-associated virus genomes in bacterial plasmids, Gene, 23(1):65-73 (1983).
[cited by applicant]
Le et al., SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN,
[cited by applicant]
Lebkowski et al., Adeno-associated virus: a vector system for efficient introduction and integration of DNA into a variety of mammalian cell types,
[cited by applicant]
Lenzi et al., 2014, NCBI Bookshelf, A service of the national library of medicine, National Institute of Health, Oversight and review of clinical gene transfer protocols: Assessing the role of the recombinant DNA adviso…
[cited by applicant]
Lioy et al., A role for glia in the progression of Rett's syndrome, Nature, 475:497-500 (2011).
[cited by applicant]
Maguire et al., Gene therapy for the nervous system: challenges and new strategies,
[cited by applicant]
Maqbool et al., The substrate-binding protein in bacterial ABC transporters: dissecting roles in the evolution of substrate specificity,
[cited by applicant]
Marks et al., Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial, Lancet Neurol., 7…
[cited by applicant]
McAllister et al., Mechanisms of glucose transport at the blood-brain barrier: an in vitro study,
[cited by applicant]
McCarty et al., Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo, Gene Ther., 10(26):2112-8 (2003).
[cited by applicant]
McCarty et al., Self-complementary AAV Vectors; Advances and Applicaitons, Amer. Soc. Gene. Ther., 16(10):1648-56 (2008).
[cited by applicant]
McCarty et al., Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis, Gene Therapy. 8:1248-1254 (2001).
[cited by applicant]
McIlwain, “Chemical and enzymic make-up of the brain during development” IN: McIlwain, Biochemistry and the Central Nervous System, London: Churchill Livingstone (1966).
[cited by applicant]
McLaughlin et al., Adeno-associated virus general transduction vectors: analysis of proviral structures, J. Virol., 62(6):1963-73 (1988).
[cited by applicant]
Mingozzi et al., Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges,
[cited by applicant]
Monani et al., A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy, J. Cell Biol., 160(1):41-52 (2003).
[cited by applicant]
Monani et al., The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy, Hum. Mol. Genet., 9(3):333-9 (2000).
[cited by applicant]
Mori et al., Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein, Virology, 330(2):375-83 (2004).
[cited by applicant]
Muzyczka, Use of adeno-associated virus as a general transduction vector for mammalian cells,
[cited by applicant]
Narver et al., Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition, Ann. Neurol., 64(4):465-70 (2008).
[cited by applicant]
NCBI Accession No. U30894.1, Human N-sulphoglucosamine sulphohydrolase mRNA, complete cds, dated Feb. 2, 1996.
[cited by applicant]
Oertle et al., Nogo-A inhibits neurite outgrowth and cell spreading with three discrete regions, J. Neurosci., 23(13):5393-406 (2003).
[cited by applicant]
Olsen et al., Intrathecal iohexol-distribution following cervical myelography, postmyelographic registration of adverse effects, psychometric assessment and electroencephalographic recording,
[cited by applicant]
Oprea et al., Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy, Science, 320(5875):524-7 (2008).
[cited by applicant]
Pacak et al., Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo, Circ. Res., 99(4):e3-9 (2006).
[cited by applicant]
Palli et al., Improved ecdysone receptor-based inducible gene regulation system, Eur. J. Biochem., 270(6):1308-15 (2003).
[cited by applicant]
Papisov et al., Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS,
[cited by applicant]
Pardridge, Drug and gene targeting to the brain with molecular Trojan horses,
[cited by applicant]
Paul et al., Increased viral titer through concentration of viral harvests from retroviral packaging lines, Hum. Gene Ther., 4(5):609-15 (1993).
[cited by applicant]
Penta, Sulla colorazione vitale del sistema nervoso central negli animali neonati,
[cited by applicant]
Perabo et al., Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus, The Journal of Gene Medicine. 8:155-162 (2005).
[cited by applicant]
Perrin et al., An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: use of serum-free medium and perfusion-reactor system, Vaccine, 13(13):1244-50 (1995).
[cited by applicant]
Ralph et al., Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model, Nat. Med., 11(4):429-33 (2005).
[cited by applicant]
Rastegar et al., MECP2 isoform-specific vectors with regulated expression for Rett syndrome gene therapy, PLoS One, 4(8):e6810 (2009).
[cited by applicant]
Ratcliff et al., Cognitive and affective changes after myelography: A Comparison of Metrizamide and Iohexol,
[cited by applicant]
Reichenbach et al., pp. 19-35 IN: Kettemann et al., Neuroglia, 2nd ed., New York: Oxford University Press (2004).
[cited by applicant]
Risau et al., Development of the blood-brain barrier, Trends Neurosci., 13(5):174-8 (1990).
[cited by applicant]
Risau et al., Differentiation-dependent expression of proteins in brain endothelium during development of the blood-brain barrier, Dev. Biol., 117(2):537-45 (1986).
[cited by applicant]
Robinson et al., Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome, Brain, 135(Pt. 9):2699-710 (2012).
[cited by applicant]
Royo et al., Specific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicity, Brain Res., 1190:15-22 (2008).
[cited by applicant]
Rubin et al., A cell culture model of the blood-brain barrier,
[cited by applicant]
Ruffing et al., Mutations in the carboxy terminus of adeno-associated virus 2 capsid proteins affect viral infectivity: lack of an RGD integrin-binding motif, J. Gen. Virol., 75(Pt. 12):3385-92 (1994).
[cited by applicant]
Samulski et al., Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells, Proc. Natl. Acad. Sci. USA, 79(6):2077-81 (1982).
[cited by applicant]
Samulski et al., Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression, J. Virol., 63(9):3822-8 (1989).
[cited by applicant]
Saunders et al., On the progestational activity of 17alpha-ethynyl-17-hydroxy-5(10)-estren-3-one (norethynodrel), Endocrinology, 60(6):804-5 (1957).
[cited by applicant]
Schlageter et al., Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties, Microvasc. Res., 58(3):312-28 (1999).
[cited by applicant]
Schnepp et al., Highly purified recombinant adeno-associated virus vectors. Preparation and quantitation,
[cited by applicant]
Schuster et al., Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse,
[cited by applicant]
Senapathy et al., Molecular cloning of adeno-associated virus variant genomes and generation of infectious virus by recombination in mammalian cells, J. Biol. Chem., 259(7):4661-6 (1984).
[cited by applicant]
Shim et al., Nonviral delivery systems for cancer gene therapy: Strategies and challenges,
[cited by applicant]
Siegel et al., Francis Crick's legacy for neuroscience: between the alpha and the Omega, PLoS Biol., 2(12):e419 (2004).
[cited by applicant]
Sinnett et al., Recent endeavors in MECP2 gene transfer for gene therapy of Rett syndrome,
[cited by applicant]
Skene et al., Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state, Mol. Cell, 37(4):457-68 (2010).
[cited by applicant]
Snyder et al., Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery,
[cited by applicant]
Sobue et al., Induction of blood-brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors,
[cited by applicant]
Sondhi et al., Correction of the lysosomal storage defect in mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal injection of AAV serotype rh. 10 vector expressing the human,
[cited by applicant]
Srivastava et al., Nucleotide sequence and organization of the adeno-associated virus 2 genome, J. Virol., 45(2):555-64 (1983).
[cited by applicant]
Steinfeld et al., Late Infantile Neuronal Ceroid Lipofuscinosis: Quantitative Description of the Clinical Course in Patients With CLN2 Mutations,
[cited by applicant]
Stern et al., Platelet lipoxygenase in spontaneously hypertensive rats, Hypertension, 27(5):1149-52 (1996).
[cited by applicant]
Stewart et al., Interendothelial junctional changes underlie the developmental ‘tightening’ of the blood-brain barrier, Brain Res., 429(2):271-81 (1987).
[cited by applicant]
Stoodley et al., Effect of Adenovirus-mediated Nitric Oxide Synthase Gene Transfer on Vasospasm after Experimental Subarachnoid hemorrhage, Nuerosurg., 46(5):1193-1203 (2000).
[cited by applicant]
Storek et al., Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain, PNAS. 105:1055-1060 (2008).
[cited by applicant]
Su et al., Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors,
[cited by applicant]
Suzuki et al., Are animal models useful for understanding the pathophysiology of lysosomal storage disease?,
[cited by applicant]
Towne et al., Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery, Molecular Pain. 5:1-17 (2009).
[cited by applicant]
Traschin et al., A human parvovirus, adeno-associated virus, as a eucaryotic vector: transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase, Mol. Cell Biol., 4:2072-81 (1984…
[cited by applicant]
Tratschin et al., Adeno-associated virus vector for high-frequency integration, expression, and rescue of genes in mammalian cells, Mol. Cell Biol., 5(11):3251-60 (1985).
[cited by applicant]
Turner et al., Administration of substances to laboratory animals: routes of administration and factors to consider,
[cited by applicant]
Urlinger et al., Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity, Proc. Natl. Acad. Sci. USA, 97(14):7963-8 (2000).
[cited by applicant]
Verkman, Aquaporin water channels and endothelial cell function, J. Anat., 200(6):617-27 (2002).
[cited by applicant]
Vestergaard et al., Central Nervous System Reactions to Cervical Myelography,
[cited by applicant]
Virgintino et al., Immunolocalization of tight junction proteins in the adult and developing human brain, Histochem. Cell Biol., 122(1):51-9 (2004).
[cited by applicant]
Vorbrodt et al., Localization of alkaline phosphatase activity in endothelia of developing and mature mouse blood-brain barrier,
[cited by applicant]
Wang et al., Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart, Nat. Biotechnol., 23(3):321-8 (2005).
[cited by applicant]
Wang et al., Decreased synaptic activity shifts the calcium dependence of release at the mammalian neuromuscular junction in vivo, J. Neurosci., 24(47):10687-92 (2004).
[cited by applicant]
Wang et al., Expansive gene transfer in the rat CNS rapidly produces amyotrophic lateral sclerosis relevant sequelae when TDP-43 is overexpressed,
[cited by applicant]
Watson et al., Postnatal growth and morphological development of the brain: a species comparison, Birth Defects Res. B Dev. Reprod. Toxicol., 77(5):471-84 (2006).
[cited by applicant]
Wolburg et al., Tight junctions of the blood-brain barrier: development, composition and regulation, Vascul. Pharmacol., 38(6):323-37 (2002).
[cited by applicant]
Wolburg, pp. 77-107 IN: Dermietzel et al., (eds.), Blood-Brain Interfaces—from Ontogeny to Artificial Barriers, Wiley-VCH (2006).
[cited by applicant]
Worgall et al., Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA, Hum. Gene Ther., 19(5):463-74 (2008).
[cited by applicant]
Wu et al., Optimization of Self-complementary AAV Vectors for Liver-directed Expression Results in Sustained Correction of Hemophilia B at Low Vector Dose, The American Society of Gene Therapy. 16:280-289 (2008).
[cited by applicant]
Wu et al., Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes, Journal of Virology. 80:11393-11397 (2006).
[cited by applicant]
Xiao et al., Gene therapy vectors based on adeno-associated virus type 1,
[cited by applicant]
Yamanaka et al., Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis,
[cited by applicant]
Zincarelli et al., Analysis of AAV Serotypes 1-9 Mediated Gene Expression and Tropism in Mice After Systemic Injection, Molecular Therapy. 16:1073-1080 (2008).
[cited by applicant]
Foust et al. Retraction Note: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN, Nature Med. 40: 1692 (2022).
[cited by applicant]